CannMed Coffee Talk

Alisha Holloway is the Chief Scientific Officer at Phylos where she leads the R&D group that focuses on foundational genomic research, development of high-throughput genetic and chemical testing capabilities, discovery of genetic markers, and the development of new cannabis varieties via classical and marker-assisted breeding. At CannMed 26, she will present “Enhancing Cannabis Quality via Marker-Assisted Selection for Improved Solventless Extraction Yield” During our conversation, we discuss: What solventless extraction is and why it’s gaining popularity The traits that make a cannabis plant a “good washer” How Alisha's team designed and conducted a washability study across hundreds of plant samples How they identified genetic markers for good washers that hold up across diverse genetic backgrounds How marker-assisted selection accelerates the breeding process Thanks to This Episode’s Sponsor: The Cannabis Research Center & Coalition The Cannabis Research Center & Coalition (CRC), founded by Dr. Allison Justice, is a professional group dedicated to advancing cannabis cultivation and post harvest processing. CRC partners with Universities and The Hemp Mine LLC, an industry leader in cannabis genetics and production, to tackle the cultivation and post harvest challenges facing today's cannabis industry. Their cooperative research model, inspired by successful horticulture and greenhouse research collaborations, allows members to benefit from pooled resources, gaining access to cutting-edge, science-based research at a fraction of the cost. Learn more at cannabisrc.org Additional Resources Phylos.bio, Instagram, Linkedin [Blog] What Makes a Cannabis Variety “Wash Well”? The Science Behind High-Yield Hash Plants https://www.instagram.com/shwale/ Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast CannMed Archive

Morgan Keefer is a Board Member for the Institute of Cannabis Science, and an experienced cannabis testing laboratory accreditation professional. She has presented at conferences, including CannMed, Pittcon, and Cannabis Science Conference regarding the importance of inter-laboratory comparison and method validation for the cannabis industry. At CannMed 26, Morgan will present Frequently Identified Nonconformances Applicable to Cannabis Testing, which will explore some of the challeges that come with operating a cannabis lab as well as opportunities for improvement. During our conversation, we discuss: Cannabis labs must be ISO/IEC 17025 accredited to prove they are competent to test for potency, contaminants, and other critical safety markers that protect consumers. Inconsistent state regulations and federal illegality create unique challenges for cannabis labs, including the need to rapidly validate new test methods as rules change. Sample manipulation by producers (i.e., bleaching samples or inflating potency) is a real problem that undermines lab results and puts consumers at risk. Many labs fall short on method validation and measurement uncertainty, sometimes reporting results for years without fully validating their methods across all product types. Consumers can protect themselves by requesting certificates of analysis, asking labs to confirm their results directly, and watching for measurement uncertainty disclosures. Thanks to This Episode's Sponsor: CANN Since 2015, CANN has been building a strong network of scientists in the cannabis space to promote scientific innovation, safety, and development through education, research, and the empowerment of the scientific community. To learn more about what CANN has to offer please visit their website at www.cann-acs.org. Additional Resources Institute of Cannabis Science Tip Line – tipline@cannsci.org  Coalition for Cannabis Worker Safety – Cannabisworkersafety@gmail.com Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast CannMed Archive

Dr. Harold Hom is the Founder of PhytoRX. He has dedicated his career to the art and science of nanoemulsions, transforming plant-derived active ingredients into stable, predictable and effective formulations. He founded PhytoRX is to bring consistency and efficacy into the plant-based therapeutics, and  give clinicians a tool they can confidently use. At CannMed 26, Harold will Moderate a panel titled “Drink Your Cannabionoids – How it changes cannabis research and patient care”, which brings together leading clinicians, researchers, and innovators to explore how emulsion-based cannabinoids are improving outcomes in oncology, geriatrics, and clinical trials.  During our conversation, we discuss:  How cannabis emulsion technology solvers composition, degradation, and absorption challenges in medical cannabis How turning oil-based cannabinoids into water-compatible emulsions improves bioavailability, dosing precision, and patient adherence How emulsion-based products improve the “therapeutic window” via predictable PK profiles that smoking, tinctures, and edibles can’t match Why drinking cannabinoids better fits patients' existing habits, afterall, people are already drinking fluids throughout the day. A preview of the CannMed Emulsion Panel  and more  Thanks to this Episode's Sponsor: PhytoRX  PhytoRX was born from the expertise of Vertosa, a pioneer in advanced infusion technology with years of experience delivering precision and consistency for next-generation botanical therapeutics. The product improves on traditional cannabinoid formats by delivering accurate dosing, rapid absorption, optimized bioavailability, and ease of use.  Go to phytorx.co to learn more, and if you decide to give it a try, use promocode CannMed at checkout to get 15% off. Additional Resources PhytoRX Register for CannMed 26 Today

Dr. Hemant Kumar Bid is a top educator in the field of Biotechnology and Medical cannabis. He serves as Program Director for the Morehouse School of Medicine, using his extensive background in biotechnology research and cannabinoid research to educate graduate students and infuse the industry with science-backed legitimacy. Recently, Hemant has become deeply engaged with Artificial Intelligence and Machine Learning through his academic, clinical, and program development work.  During our conversation we discuss: How AI and machine learning are accelerating drug discovery, enabling personalized treatment, and analyzing complex genomic and clinical data. How the Morehouse School of Medicine is updating its biotechnology curriculum to integrate AI/ML  Why the accuracy of AI predictions depends entirely on data quality fed into the models, making standardization, diverse representation, and clean datasets critical for success How AI can help reduce trial-and-error prescribing in favor of personalized care for specific patient conditions, optimized dosing, and potential adverse effects and/or drug interactions. Major challenges that need to be overcome before AI and ML can truely transform medical cannabis treatment.  Thanks to This Episode’s Sponsor: Tikun Olam Tikun Olam is the world’s first licensed medical cannabis company. With over 20 years of clinical cannabis research, Tikun Olam has conducted 7 clinical trials and published over two dozen academic journal studies using its heirloom cultivars. Tikun Olam products are designed for specific needs: pain relief, better sleep, digestive comfort, and neurological balance — all standardized for consistent, predictable results. If you’re curious to learn more about their products or research, they even offer a free one-on-one consultation with a licensed nurse. Shop online or find a dispensary at tikunolam.com Additional Resources Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast

Ansley Burtch is a Post-Baccalaureate Scholar in the Department of Entomology and Plant Pathology at the University of Tennessee. Her undergraduate and post-baccalaureate research focuses on plant-pathogen interactions using computational genomics and transcriptomic approaches. She has also investigated the production of toxins by fungi and their impacts on human health.  At CannMed 26 she will present “Decoding Natural Viroid Tolerance: Genomic and Transcriptomic Analysis of HLVd Response in Cannabis”. During our conversation, we discuss: Why the research team decided to pursue natural tolerance as a Hop Latent Viroid defense strategy rather than resistance Real-world observations that identified the Jamaican Lion cultivar as having a natural tolerance that keeps the viroid localized in the roots Creating a chromosome-scale genome assembly of Jamaican Lion to enable more confident identification of candidate genes and pathways involved in tolerance. Early findings suggesting the viroid activates genes that control root metabolism, as well as the anthocyanin and betalin pathways, during infection. The long-term goal, to identify specific genetic markers linked to tolerance so breeders can intentionally select for viroid-tolerant cultivars. Thanks to This Episode’s Sponsor: Advanced Nutrients Advanced Nutrients will once again be a partner level sponsor for the CannMed 26 Summit and this year they have put together an amazing package for cultivators.  Advanced Cultivator Package which includes  Full Access to all the presentations, networking events, and meals at the CannMed 26 summit  Accomodations at the Hyatt Regency Lake Tahoe  An elite package of Advanced Nutrients 8th Gen Fertilizers – enough for a complete crop valued at $11,126* 1x StrainSEEK® Whole Genome Sequence, valued at $547Provided By: Medicinal Genomics In all worth upwards of $14,000, but you can get it for just $3,499  Check out the details at cannmedevents.com/packages  Additional Resources Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast

Manuel Sosa leads the analytical testing and research team at Abstrax Tech. In his role, Manny uses advanced techniques such as Comprehensive two-dimensional gas chromatography and HPLC to conduct rigorous tests and refine Abstrax SOPs to improve precision and efficiency.  At CannMed 26, Manny will present “Temperature-Controlled Butane Extraction Minimizes Waxes While Preserving Cannabinoids and VOCs”, which explores how temperature affects the quality of butane extracts. During our conversation, we discuss  Butane extraction temperature's significant effect on wax content How cannabinoid and terpene yields remain stable across temperature ranges How Manny's team chemically quantified and characterized waxes and fats using 2D gas chromatography Whether colder extraction temperatures can eliminate the need for winterization Why inhaled alkanes are an open safety question worth studying  Thanks to This Episode's Sponsor: CANN Since 2015, CANN has been building a strong network of scientists in the cannabis space to promote scientific innovation, safety, and development through education, research, and the empowerment of the scientific community. To learn more about what CANN has to offer please visit their website at www.cann-acs.org. Additional Resources Abstrax Tech Research Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast CannMed Archive

Dr. Mohsin Maqbool is a pediatric neurologist and sleep specialist based in Dallas–Fort Worth, Texas. His work focuses on the intersection of neurodevelopment, sleep, and cannabinoid therapeutics in autism spectrum disorder. He is particularly interested in how cannabinoid formulations may influence sleep regulation, behavior, and quality of life in children with autism. At CannMed 26, Mohsin will present “Autism, Sleep, and Medicinal Cannabis: Evaluating 18-Month Efficacy and Safety Outcomes” During our conversation, we discuss: The gaps in current sleep medicine for children with Autism Spectrum Disorder Results from Mohsin's 18-month longitudinal study including improvements to total sleep time, sleep onset and maintenance, and overall quality of sleep The method of finding the effective dose for each patient  Cannabinoids' effect on the duration of REM sleep and what the daytime implications are  Thinking of cannabis as a tool to supplement conventional ASD medications and not a replacement  Future research directions – using wearables and EEG to investigate how cannabinoids affect sleep architecture and brain physiology, as well as using biomarkers to see whether patients are a good candidate for cannabinoid therapies Thanks to This Episode's Sponsor: The Society of Cannabis Clinicians  The Society of Cannabis Clinicians is a nonprofit professional association of physicians and other healthcare providers. It provides continuing education—for clinicians, patients, and all concerned about the medical use of cannabis and best practices in clinical care. SCC physicians have been monitoring cannabis use by patients for 20 years and have compiled a wealth of clinical evidence and treatment strategies that will be validated by clinical trials in the years ahead. To learn more about SCC and to join visit cannabisclinicians.org. Additional Resources Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study [Book] Cannabis Is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain by Dr. Bonni Goldstein Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast CannMed Archive

Dr. Zamir Punja is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases and the applications of plant biotechnology for disease management. Since 2018, his work has focused on cannabis, identifying and describing a range of previously unreported pathogens affecting the crop and evaluating various methods for disease management.  Zamir is CannMed regular, having presented at 5 previous events. His presentations are always a highlight of the event because they often feature stunning electron microscope images showing plant structures and pathogens up close. In fact, his CannMed 22 presentation about glandular trichomes has gotten more than 300,000 views on our YouTube page, making it the most viewed CannMed presentation.  Zamir will again present at CannMed 26, this time about non-glandular trichomes in a presentation titled “Non-glandular trichomes in cannabis plants can secrete salts”.  During our conversation, we discuss: Non-glandular trichomes: What they are and what they do. How leaf spots, initially mistaken for disease, led to the finding that cannabis secretes excess fertilizer salts through these trichomes. Theories on why the plant would develop the ability to actively excrete excess salts. Practical guidance for cultivators on how to distinguish overfertilization from disease. Future research directions — comparing salt-tolerant vs. non-tolerant strains under varying salinity levels and exploring whether this mechanism explains cannabis’s resilience in drought-prone, high-salt environments. Thanks to This Episode’s Sponsor: Advanced Nutrients Advanced Nutrients will once again be a partner-level sponsor for the CannMed 26 Summit, and this year they have put together an amazing package for cultivators that includes: Full Access to all the presentations, networking events, and meals at the CannMed 26 summit  Accommodations at the Hyatt Regency Lake Tahoe  An elite package of Advanced Nutrients 8th Gen Fertilizers – enough for a complete crop valued at $11,126* 1x StrainSEEK® Whole Genome Sequence, valued at $547 – Provided by Medicinal Genomics That’s a $14,000 value for just $3,499!   Learn more at cannmedevents.com/package-options Additional Resources [Article] Non-glandular trichomes (epidermal hairs) in cannabis plants are capable of excreting nutrient salts under excessive fertilizer regimes [Video] Exploring the fascinating development of cannabinoid-producing trichomes Register for CannMed 26 Meet the CannMed 26 Speakers Review the Podcast CannMed Archive

Dr. Codi Peterson is a pediatric pharmacist with over a decade of experience specializing in acute care and pediatric emergency medicine. He currently serves as a clinical pharmacist at Rady’s Children’s Health of Orange County, where he works night shifts in the Emergency Department and applies his expertise to optimize medication safety and therapeutic outcomes in children. Beyond the hospital, Codi is deeply committed to education and mentorship. He is an Associate Clinical Professor at the University of California, Irvine, where he teaches cannabis pharmacology and therapeutics, and a guest lecturer at OCEMT, instructing paramedics and firefighters in applied pharmacology. He is also an active researcher on Cannabinoid Hyperemesis Syndrome (CHS), having led one of the largest patient surveys on the condition to date. At CannMed 26, Codi will share the results of that study in a presentation titled, “Through the Eyes of a Patient: Integrating Story and Science to Demystify CHS”.  During our conversation, we discuss:  Defining CHS and explaining why it is difficult to research  Cannabis use patterns among CHS sufferers  Whether contaminants and pesticides play a role in developing CHS  The prodromal phase and early warning signs of CHS  Sex-based differences in CHS patients  Understanding the biological mechanisms behind the development of CHS  and more Thanks to This Episode’s Sponsor: The Cannigma  The Cannigma takes an evidence-based approach to cannabis content – from safety to cooking to medical research – and makes all the information digestible and useful. They are committed to making sure scientific information is accessible to anyone who needs it – be it to relieve their own suffering or that of a loved one, to learn a bit more, or even just for fun.  Learn more at cannigma.com  Additional Resources Surveying Cannabinoid Hyperemesis Syndrome Patients with Megan Mbengue and Codi Peterson [Video] Cannabinoid Hyperemesis Syndrome What You Need to Know [Video] what-is-chs.com Connect with Codi (Instagram, LinkedIn) The Cannigma Register for CannMed 26 – Early Bird Ends February 20th!

Dr. Beth Weise is the Research and Overdose Prevention Coordinator for The Sidewalk Project, a non-profit organization that aids unhoused, drug-using, survivor & sex worker populations by providing direct services including crisis response, system advocacy, wound care, job placement, medication-assisted treatment (MAT), and creative community resources for mental health. Her work aims to influence future drug policy with novel evidence-based research that also advocates and empowers people who use drugs to feel safe and prevent fatal overdose. At CannMed 26, Beth will present “Cannabidiol to Mitigate Opioid Induced Respiratory Depression“. During our conversation, we discuss: What causes Opioid Induced Respiratory Depression and how cannabinoids play a role How CBD can be used in combination with Naloxone to reduce withdrawal-related side effects How Beth's research can be applied in real-world scenarios Thanks to This Episode's Sponsor: Humanity Heroes Humanity Heroes provides compassionate support to the unhoused community by delivering essential supplies and resources directly to those in need. Humanity Heroes partners with other nonprofits by empowering them to extend their reach and impact within their own communities. Together, they strive to create a world where every person has access to the resources and support they need to thrive. Learn more at JoinHumanityHeroes.org Additional Resources: THRRIV.org [Webinar] Bridging the Gap: Tech-Supported Peer Connections to Reduce – Overdose Fatalities – Register for CannMed 26

Dr. Mandip Sachdeva is currently a Professor and Section leader, Pharmaceutics at College of Pharmacy at Florida A & M University (FAMU), Tallahassee, Florida. Over his career, Mandip has delivered more than 250 plenaries, keynote and invited talks in international events and meetings and produced more than 190 original publications.His research interests include cancer drug delivery, 3D-printing of tumor cells, and formulating and developing targeted nanoparticles, exosomes and cannabinoids for cancer treatments. During our conversation, Mandip previews his CannMed 26 oral presentation titled, “Cannabigerol Potentiates Chemotherapy through Multi-Modal Tumor Suppression in Pancreatic Cancer“, which includes insights into his research on using cannabinoids (particularly CBG) to treat pancreatic cancer—one of the most difficult cancers to treat. We cover:  The process Mandip's team used to determine CBG had the best anti-cancer effects against pancreatic cancer  CBG's mechanism of action, which targets multiple pathways related to immune regulation, cell death, and tumor migration control Why cannabinoids are best used as adjuncts to chemotherapy and not as a standalone treatment  Higher doses of CBG (up to 100 mg/kg) were non-toxic and further extended survival when combined with reduced chemo doses Future research directions, including new combinations of cannabinoids and chemotherapy as well as new formulations for better absorption and bioavailability  Thanks to This Episode's Sponsor: Healer  Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer's distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O.  Learn More at healer.com

Dr. Ryan Vandrey is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins. Dr. Johannes Thrul is an Associate Professor at Johns Hopkins. They both work for the Cannabis Health & Research Initiative, which is a collaboration between two organizations with years of experience in medicinal cannabis research: Johns Hopkins University and Realm of Caring. Simply put, CHRI is a platform of data collection and dissemination focused on the health outcomes of medicinal cannabis at the patient level, and they have created a number of valuable resources to help cannabis medicine researchers, including: A data repository that contains de-identified data collected through CHRI Research Library that contains more than 3000 published scientific articles related to the health effects of cannabis A set of validated questionnares that clinicians can use when speaking to patients about cannabis – and more The CHRI is also currently recruiting participants for their National Cannabis Study, which is a collection of firsthand experiences with medicinal cannabis among individuals with various health conditions. Specifically, they are looking for participants who plan to use cannabis but have not yet started cannabis use. So if that's you or someone you know, we highly suggest you consider participating in the study because the research has the potential to impact best practices in healthcare and the cannabis industry. During our conversation, Ryan and Johannes shared more details about the CHRI and the National Cannabis Study, and I think you will agree that their mission aligns perfectly with the CannMed Community. Thanks to This Episode’s Sponsor: Realm of Caring Founded in 2013, Realm of Caring (RoC) serves anyone in need of more information about cannabinoid therapies. Through revolutionary CBD and Cannabis research, innovative education, and life-changing grants, RoC seeks to facilitate and encourage the mainstream acceptance of transformative, plant powered therapies to benefit individuals and families and serve healthcare providers as well as the hemp and cannabis industries. Learn more at realmofcaring.org Additional Resources Cannabis Health Research Initiative website – cannabisandhealth.org

Dr. Bonni Goldstein is the Medical Director of Canna-Centers Wellness & Education, a leading cannabis medicine specialty practice, and the CEO of GoldsteinWellness.com, an educational platform dedicated to helping licensed healthcare professionals incorporate medical cannabis into their practices. Bonni has evaluated thousands of patients for medical cannabis treatment, with a special focus on treating children with intractable epilepsy, autism, and cancer. She authored the book Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain, and serves on the board of the International Alliance for Cannabinoid Medicine and Autism Safe Haven. Bonni has also been the medical director for the CannMed Medical Practicum since 2022. During our conversation, we discussed: Exciting updates to the CannMed Medical Practicum, including new topics (sports and recovery, cannabinoids and pregnacy, Pharmacokinetics and Product Formulation, and more) Findings from a California medical cannabis study showing diverse patients, high efficacy, and research gaps The importance of medical guidance when using cannabinoid therapies for complex conditions Safety issues with synthetic or semi-synthetic cannabinoids, and the importance of natural compounds and dosing education Goldstein Wellness as a resource for clinicians and patients, providing education, patient-clinician connections, and vetted product access Thanks to This Episode’s Sponsor: The Society of Cannabis Clinicians The Society of Cannabis Clinicians is a nonprofit professional association of physicians and other healthcare providers. It provides continuing education—for clinicians, patients, and all concerned about the medical use of cannabis and best practices in clinical care. SCC physicians have been monitoring cannabis use by patients for 20 years and have compiled a wealth of clinical evidence and treatment strategies that will be validated by clinical trials in the years ahead. To learn more about SCC and to join visit cannabisclinicians.org. Additional Resources GoldsteinWellness.com CannMed Medical Practicum

No episode this week. We had to call a last-minute audible. You may have heard that the bill to restart the federal government contained language that would ban hemp products containing THC, which has sent the entire hemp industry, including many CannMed supporters and contributors into chaos. As a result, the guest we had scheduled for this week's episode asked to reschedule, which we were happy to oblige. But don't worry, we will be back with a new episode next week featuring the always wonderful Bonni Goldstein. She has some exciting details to share about the CannMed 26 Medical Practicum, which is going to feature tons of new topics. So please tune in for that one. In the meantime, I'd like to remind everyone that we are accepting abstracts for the CannMed 26 Summit through the end of the week. The deadline is this Saturday, November 15th. Submit at cannmedevents.com/apply If you have done any novel research in the areas of cannabis science, medicine, cultivation, or safety and testing, we encourage you to submit an abstract for consideration. If selected, not only will you have the opportunity to present your work to the industry leaders in attendance at CannMed 26, but a recording of the presentation will be added to the CannMed Archive and Medicinal Genomics YouTube page for additional exposure after the event. You will also get an invitation from me to appear on the CannMed Coffee Talk podcast, if that's something you're interested in. See you next week!

Dr. Hemant Kumar Bid is a top educator in the field of Biotechnology and Medical Cannabis, where he uses his extensive background in biotechnology research and cannabinoid research to educate cannabis and biotechnology professionals and infuse the industry with science-backed legitimacy. In addition to serving as a Program Director for the Morehouse School of Medicine and teaching graduate students, Hemant also serves as a Scientific Advisor for Essentia Scientific, a company that delivers an array of cannabinoid product solutions, including acidic cannabinoids, with their patented water-as-solvent extraction technology. During our conversation, we discuss:  What are cannabinoid acids and how do they differ from the neutral cannabinoids  Why have cannabinoid acids been traditionally overlooked in research and consumer products  How THCA produces different effects than THC  Why CBDA is more bioavailable and more potent than CBD  How new extraction and stabilization techniques are helping make cannabinoids acids more accessible  and more  Thanks to This Episode's Sponsor: CANN Since 2015, CANN has been building a strong network of scientists in the cannabis space to promote scientific innovation, safety, and development through education, research, and the empowerment of the scientific community. To learn more about what CANN has to offer please visit their website at www.cann-acs.org. Additional Resources Essentia Scientific Website Email Hemant - Hibid@msm.edu Submit Your Abstract for CannMed 26 Meet the CannMed 26 Advisory Board

Caitlyn Krebs is a biotech executive with over 20 years of experience advancing therapeutics, diagnostics, and digital health innovations. She is the Co-Founder and CEO of Nalu Bio, where she leads the development of next-generation cannabinoid-inspired therapeutics with pharmaceutical-grade quality and scalability. Over her career, Caitlyn has completed more than 50 strategic partnerships and product launches across biopharma, diagnostics, and digital health. Nalu Bio recently announced positive results for a cannabinoid-based therapeutic for endometriosis, a condition that affects 200 million women worldwide. During our conversation, we discussed: Understanding Endometriosis - symptoms, diagnosis, and current treatment options How Millions of women with endometriosis are using CBD or THC to self-treat symptoms What makes the endocannabinoid system a prime target for for endometriosis How Nalu Bio uses an AI platform to accelerate the development of novel, consistent, and non-addictive cannabinoid molecules The potential for broader applications for cannabinoid-based therapeutics, similar to GLP-1 therapies The timeline for future clinical trials and potential FDA-approval Thanks to This Episode's Sponsor: The Society of Cannabis Clinicians The Society of Cannabis Clinicians' Med Cann conference offers a rare opportunity for clinicians to dive deep into the clinical realities and therapeutic potential of medical cannabis and psychedelics. Designed with healthcare providers in mind, their sessions focus on case-based learning, emerging protocols, and real-world challenges—offering practical insights that can be immediately applied in your practice. Learn more at cannabisclinicians.org and use code "CP15" to receive 15% Off Your Registration Additional Resources NaluBio.com Big Data Begins to Crack the Case of Endometriosis (UCSF) CannMed Call for Abstracts

Dr. Todd Michael is a leading researcher specializing in genome sequencing and analysis, currently serving as a Research Professor at the Salk Institute for Biological Studies and an Adjunct Professor at the University of California, San Diego.  His research has made significant contributions to understanding plant genome architecture, particularly through the study of unique and specialized plants that offer insights into adaptive strategies. His innovative work on pangenome tools and long-read sequencing technologies has advanced the understanding of how plant genomes are organized and how they adapt to specific environmental conditions. At CannMed 25, Todd presented “Cannabis Pangenome Exposes Minor Cannabinoid Pathway Potential”, which described how his team integrated 193 cannabis genomes to identify extensive genetic and structural diversity and highlight potential breeding bottlenecks. During our conversation, we discussed: What is a pangenome and why has it replaced single reference genomes Why cannabis is the most interesting plant genome Todd has worked with What has caused cannabis to be one of the world's most diverse plants How transposable elements AKA “jumping genes” contribute to cannabinoid synthase The potential risks of excluding males plants from breeding and more Thanks to This Episode's Sponsor: Advanced Nutrients Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at AdvancedNutrients.com Additional Resources Michael Lab Website CannMed Video Archive CannMed 25 Photo Gallery

Dr. Emily Lindley is Assistant Professor of Orthopedics and Director of the Colorado Cannabis Research Consortium. Her team's research aims to identify non-opioid alternatives for the treatment of chronic musculoskeletal pain. One such alternative that has gained increased recognition in recent years is medical cannabis, and her lab is currently studying the health effects of cannabis and cannabinoids for chronic musculoskeletal pain. Dr. Rachael Rzasa Lynn is a board certified in pain medicine physician and is an Associate Professor in the Department of Anesthesiology at the University of Colorado, where she is the Associate Program Director for the Pain Medicine Fellowship. Her research includes investigations in opioid pharmacology and the use of cannabis for chronic pain. Emily and Rachael co-authored a poster presented at the most recent ICRS conference titled, Recruitment Challenges in Clinical Studies of Cannabis During our conversation, we discussed: How recruitment for cannabis clinical trials differs from traditional clinical trials Why prior experience with cannabis is considered a negative for patient recruitment How legal concerns and stigma can deter cannabis-naive patients from enrolling Why the particiapnt drop out rate is higher in cannabis trials How rescheduling may affect patient recruitment future trials Thanks to This Episode's Sponsor: The Society of Cannabis Clinicians The Society of Cannabis Clinicians' Med Cann conference offers a rare opportunity for clinicians to dive deep into the clinical realities and therapeutic potential of medical cannabis and psychedelics. Designed with healthcare providers in mind, their sessions focus on case-based learning, emerging protocols, and real-world challenges—offering practical insights that can be immediately applied in your practice. Learn more at cannabisclinicians.org and use code "CP15" to receive 15% Off Your Registration Additional Resources Recruitment Challenges in Clinical Studies of Cannabis [Poster] Lindley Lab at the University of Colorado

Dr. Jose Lime is a Professor at Southern Illinois University and the principal investigator in the Cannabis Biology and Cultivation Systems lab. He and his team focus on determining how to leverage environmental controls (light intensity, duration, quality, temperature, and CO2), plant nutrition, biostimulants, and hormones to improve plant production. Moreover, the research group is developing techniques to optimize plant yields and quality based on key crop steering traits that increase sustainability and efficiency via plant physiological, biochemical, and agricultural approaches. During our conversation, we discussed several recent studies that Jose and his team have published, including: Using mechanical stimulation and high stress training to increase production of secondary metabolites Applying plant hormones to increase trichome density Assessing how drought stress affects plant yield and potency Standardizing cloning methods for plant propagation Developing standards for measuring trichome density Thanks to This Episode's Sponsor: Advanced Nutrients Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at AdvancedNutrients.com Additional Resources DrLeme.com Methyl Jasmonate and Ammonium Bicarbonate: Distinct and Synergistic Impacts on Indoor Cannabis Production Dynamics The Role of Jasmonates in Modulating Growth, Trichome Density, and Cannabinoid Accumulation in Cannabis sativa L. The Effects of Water-Deficit Stress on Cannabis sativa L. Development and Production of Secondary Metabolites: A Review From Bracts to Buds: Developing Reliable Methods for Trichome Density Assessment in Cannabis sativa L. Accumulation of Trigonelline in the Leaves of Cannabis sativa L. in Response to Water-Deficit Stress Implementation of a Standardized Cloning and Propagation Protocol for Optimizing Cannabis sativa L. Cultivation

Dr. Mark Scialdone is a recognized expert in the field of organic chemistry, specializing in natural product chemistry, including plant oil extraction, analysis, and chemical modification. He is an inventor of 37 issued US patents and has authored 17 peer-reviewed publications, during more than two decades of fundamental and product development research. He has given numerous invited lectures at more than 40 different academic institutions and international symposia. At CannMed 25, Mark participated in the Hemp-Derived Cannabinoids panel, which explored the rapid rise of products containing chemically transformed cannabinoids to exploit the 2018 Farm Bill loophole. He also presented a poster that explained the process for chemically converting cannabinoids in more detail. During our conversation we discussed: Why producers and manufacturers would want to convert one cannabinoid into another Common methods for cannabinoid conversion Safety risks associated with chemical cannabinoid conversion The legality of these compounds How these compouns and these products are affecting the legal cannabis market The therapeutic potential of novel, chemically-converted cannabinoids and more Thanks to This Episode's Sponsor: Cannabis & Tech Today Cannabis & Tech Today is the premier publication for the business, science, and innovations shaping the cannabis industry. From exclusive interviews with industry leaders to deep dives on the latest tech, they cover it all. Go to cannatechtoday.com to subscribe to their digital and print editions and gain access to exclusive interviews, brand-new technology, and thought-provoking articles from every corner of the cannabis community. Additional Resources Pre-Register for CannMed 26 for just $100 CannMed Video Archive Connect with Mark on LinkedIn The Dark Side of Cannabidiol (CBD): The Unanticipated Social and Clinical Implications of Synthetic Δ8-THC Hash Church on YouTube CANN Delta-8-THC Panel Discussion GC Separation for Identification of iso-THC Contaminants and Accurate Quantification of Δ8 -THC and Δ9-THC in Cannabis Samples

Another CannMed Summit is in the books. To all of you who joined us in Puerto Rico this year, thank you for making it our best event yet!  This year's summit brought together clinicians, regulators, researchers, cultivators, patients, and entrepreneurs from more than a dozen countries. The enthusiasm and passion that they brought to the sessions and the networking events created an amazing environment for creating lasting connections. We can't wait to see how those connections shape the future of the industry.  If you weren't able to join us this year, don't worry, you can experience at least part of the CannMed magic when we post video recordings of all the panels and oral presentations on our YouTube page and the CannMed Archive. Those will be posted in the next 30-45 days. Be sure to sign up for email alerts to receive an email when they are live.  We are already looking forward to CannMed 26 and will hopefully have details to share very soon. 2026 is the 10 year anniversary of our very first event, so we are working on some special ways to celebrate.  That's it for now. No interview today. We are still resetting following the event, but we should be back with a new episode for July 9th.   

Dr. Shiksha Gallow currently serves as the Medical Director of the Holistic Integrative Healing Institute and is notably the first and only South African to sit on the Board of Directors of the Society of Cannabis Clinicians. Dr. Gallow's passion lies in leveraging her medical and scientific expertise to develop Active Pharmaceutical Ingredients (APIs) from cannabis and other plant species to treat various conditions. She has achieved significant success in treating patients with autoimmune diseases and cancer, and she strongly advocates for patient access to safe and effective medicines that improve quality of life. At CannMed 25 she will present “Comprehensive Evaluation of the ‘Impact of Cannabinoids' on Prostate Cancer: Integrating PSA, PET/CT Scans and Patient-Related Outcomes”  During our conversation we discuss The variety of treatment options for prostate cancer and the role of cannabinoids may play Results from an empirical study that evaluated how cannabinoid treamtment impacts PSA levels PET/CT scans and patient reported outcomes  How patients were selected and grouped for the study  Future research opportunities  and more  Thanks to This Episode's Sponsor: PRICH Biotech PRICH Biotech, Corp. is a vertically integrated company dedicated to the cultivation, manufacture and dispensing of medicinal Cannabis in Puerto Rico.  With over 500,000 square feet of STATE OF THE ART facilities, Prich uses  the highest standards of agricultural and manufacturing practices to Guarantee the highest standard of medicinal cannabis. Their mission is to offer a natural and unique experience through medicinal cannabis that raises the patient's well-being and quality of life. Learn more at prichbiotech.com.  Additional Resources Dr. Gallow on Linkedin Holistic Healing Dr Gallow (Facebook) CannMed Video Archives

Morgan Keefer is the Senior Accreditation Officer at A2LA where she works with and assesses cannabis testing laboratories across the United States.  Since joining A2LA, Morgan has presented about Laboratory Shopping, Proficiency Testing, and Microbial Testing in the cannabis industry at Cannabis Science Conference, A2LA's Annual Conference and PITTCON. At CannMed 25 she will present “Accredited Methods in Cannabis Testing” which will explore many of the challenges facing cannabis testing labs. During our conversation we discuss:  The variation of cannabis testing regulations across the U.S., and how that creates challenges for multi-state labs and manufacturers. The lack of established testing standards, which leads to inconsistent results across the industry  The role organizations like AOAC and USP play in creating standard methods   How inconsistent testing results affect consumer safety  The lack of testing requirements for consumable hemp products  Thank You to This Episode's Sponsor: McKinney RSA  McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources NIHC Verify program  A2LA-NIHC Verify Hemp/Cannabis Recognition Program  A2LA Domestic Recognitions  A2LA Public Documents  Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field.  Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 25 this year and is contributing to multiple sessions, including: The Cannabinoid Hyperemesis Syndrome Panel CannMed Medical Practicum Bridging the Gap: New Findings on the Utility of CBG-Dominant and THC-Containing Hemp Products Morning Mindfulness Session We discuss: Overview of Dustin's oral presentation on CBG and its clinical use in cannabinoid medicine Current research, anecdotal evidence, and mechanisms of CBG's therapeutic effects Insights from a patient survey studying CBG and THC usage patterns, dosages, and outcomes How the 2018 Farm Bill increased patients' access to THC-containing products Using cannabinoids, especially low-dose THC and CBG, to manage dementia symptoms. Survey data on using ketamine to treat depression and pain Thanks to This Episode's Sponsor: Healer  Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer's distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O.  Learn More at healer.com Additional Resources  Healer.com  HealerCBD.com Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters – –  Review the Podcast CannMed Archive

Zamir Punja, PhD is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. At CannMed 25, Zamir will present his team's latest work investigating the microbiome of cannabis and hemp plants. Using Next-Generation Sequencing and microscopy, his team identified diverse fungi, yeasts, and bacteria across plant tissues. Their study reveals that cannabis plants host abundant microbial endophytes, which can impact plant health and product quality. Findings also highlight the influence of growing substrates and biocontrol agents on the cannabis microbiome. During our conversation, we discuss: What is the microbiome and how do microbial endophytes affect plant health Identification of common microbes found in cannabis samples, including Penicillium and Fusarium Whether meristem tissue culture is a viable microbial sterilization method The influence of sterilized vs. non-sterilized growing media How growers can use microbiome analysis for early interventions Insights into beneficial fungi like Trichoderma and Mycorrhizae Future research questions on microbial balance and seed microbiome engineering And More Thanks to This Episode's Sponsor: GrowDefender GrowDefender provides long-lasting antimicrobial protection for indoor cultivation and processing spaces. Using patented Goldshield® technology, their EPA-registered, water-based products protect surfaces from mold, mildew, bacteria, and fungi for up to 90 days. Safe, non-toxic, and easy to apply, GrowDefender helps growers reduce contamination, protect crops, and maintain cleaner, healthier environments. Learn more at growdefender.com Additional Resources Endophytes in Cannabis sativa: Identifying and Characterizing Microbes with Beneficial and Detrimental Effects on Plant Health - https://pmc.ncbi.nlm.nih.gov/articles/PMC12030312/ Exploring the fascinating development of cannabinoid-producing trichomes - https://youtu.be/Avhr8XjsBTU?si=nbYpjuoMMnKVqF6X Register for CannMed 25 - https://cvent.me/emBPno Meet the CannMed 25 Speakers and Poster Presenters - https://cannmedevents.com/speakers/ - Review the Podcast - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804 CannMed Archive - https://cannmedevents.com/cannmed-video-archives/

Dr. Dedi Meiri is an Associate Professor at the Technion Institute where he heads the Laboratory of Cancer Biology and Cannabinoid Research. The lab investigates the vast therapeutic potential of secondary metabolites from cannabis and other herbs, algae, and psychedelic mushrooms; and reveals how these naturally occurring metabolites affect various types of cancer, inflammatory diseases, and disorders of the nervous system Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees that seek to advance the fundamental understanding of optimal cannabis and other psychedelic plant usage and curtailing adverse effects. At CannMed 25, Dedi will present "Cannabis as a Therapy Across Diverse Cancer Types: Milestones and Insights from a Decade of Research", which will discuss his lab's work investigating whether Cannabis can serve as a primary pharmaceutical treatment for cancer. We discuss: The wide range of clinical applications for cannabis medicine, including cancer, epilepsy, sleep disorders, Alzheimer's, and women's health issues like endometriosis. How cannabis' entourage effect challenges the traditional one-drug-one-target model. How many powerful cannabinoids are overlooked by standard lab testing methods—even though they exist in significant quantities and show therapeutic potential. Israel's Medical Cannabis Model, which treats cannabis like a pharmaceutical, with prescriptions, clinical oversight, and growing physician acceptance. The goal is to provide evidence-based, accurate treatments that tailor cannabis therapies to specific health conditions and individual needs. Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com Additional Resources Dedi Meiri Publications on Google Scholar Dedi Meiri on Linkedin Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Michael Petersen has over 38 years of experience as a researcher and mentor in both the private and public plant biotech space. He has over 50 issued patents and his work in plant transformation and gene expression is a passion. Mike has worked on many genetic engineering/editing contracts with entities across the globe, and he now focuses on innovative hemp research. At CannMed 25, Mike will share his team's latest efforts to transform cannabis and hemp plants using gene editing and genetic engineering in a presentation titled, “Creation of Novel Traits Through Genetic Engineering and Editing of Cannabinoid, Terpene, and Flavonoid Pathways in Cannabis sativa” During the conversation, we discussed: The difference between gene editing and genetic engineering How gene editing and genetic engineering methods have changed over the years Potential applications of gene editing and genetic engineering in cannabis and hemp Benefits and challenges versus traditional breeding The Wisconsin Crop Innovation Center's gene editing service, which is available to researchers and cultivators Thanks to This Episode's Sponsor: Kannapedia.net Kanapedia.net is the world's most comprehensive cannabis genomic library, featuring more than 2,200 genomic reports on cannabis and hemp varieties from around the globe. Kannapedia.net reports are easily searchable and contain Visualizations and Variant Tables that highlight high-impact variants in genes of interest. For example, you can see a report for the Badger G variety that Mike Petersen's team edited to break the CBDA synthase gene. In fact, you can see the drop out in the CBDA coverage chart on that report. . Visit Kannapedia.net to learn more. Additional Resources Wisconsin Crop Innovation Center Email Mike Michael Petersen on Linkedin Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Israel Gasperin is a visionary entrepreneur, engineering scientist and the founder of Zentrela, a company dedicated to transforming cannabis research through advanced neurotechnology and AI. Under Israel's leadership, Zentrela developed the Psychoactive Effect Level (PEL) metric, an innovative EEG-based measure capable of objectively assessing cannabis products' psychoactive potency. By combining wearable EEG technology with AI-driven EEG analysis, the PEL metric provides cannabis producers, researchers, and regulators with a non-invasive and cost-effective way to quantify product effects and maintain quality control.  At CannMed 25, Israel will share results from over 10,000 EEG scans of consumers using a wide range of cannabis products in his oral presentation titled “Cannabis Effect Research Driven by EEG Technology and Machine Learning”. During our conversation, we discuss:  How Zentrela's wearable EEG technology got its start measuring drowsiness in truck drivers   The unreliability of consumer feedback with regards to cannabis product effects  How the PEL metric was created to measure the unique psychoactive effects of cannabis How producers can use PEL to objectively measure the quality and effectiveness of cannabis products beyond cannabinoid percentages  Research findings that show THC% and PEL% are not directly correlated  and more  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Zentrela Website Israel Gasperin on LinkedIn Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Shawna Vreeke, PhD is Head of Research at True Terpenes, where she is instrumental in developing and maintaining the rigorous safety and quality protocols the brand is known for. Shawna is an active advocate for science-based safety parameters to protect consumer health and has worked with policymakers to implement sensible regulations to protect public health and maintain access to regulated cannabis products. She has multiple peer-reviewed papers on vape safety, and most recently, her work has been adopted into two ASTM global standards. At CannMed 25 Shawna will present Toxicological Risk in Cannabis Vapes: Exogenous Additives and Their Implications for Consumer Safety. It will highlight specific higher-risk ingredients and identify how prevalent they are in vaporization products currently in the cannabis market.  During our conversation we discussed:  The main components of cannabis vape products  How and why exogenous ingredients are added to vape products How toxicological risks are evaluated based on hazard and exposure level  Why one can't assume that safe food ingredients are also safe for inhalation  Why risk-assessment based regulations are a better approach to outright bans on flavors and more  Thank You to This Episode's Sponsor: McKinney RSA  McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources True Terpenes website Connect with Shawna Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Dr. Staci Gruber is the Director of the Cognitive and Clinical Neuroimaging Core at McLean Hospital's Brain Imaging Center and an Associate Professor of Psychiatry at Harvard Medical School. Dr. Gruber launched Marijuana Investigations for Neuroscientific Discovery (MIND) in 2014, the first ever program of its kind designed to clarify the long-term impact of medical cannabis use. MIND supports numerous projects that aim to address the impact of medical cannabis on a number of important variables including cognition, brain structure and function, clinical state, quality of life, pain, sleep, and other health-related measures. As director of MIND, Dr. Gruber has generated major contributions to the field as the first to assess medical cannabis patients longitudinally, first to acquire neuroimaging data in medical cannabis patients, and as Principal Investigator of the first clinical trial of a full-spectrum, high-cannabidiol (CBD) product, which she specifically formulated to treat anxiety. Additional, novel clinical trials have been approved and are pending or currently underway. At CannMed 25 Staci will share findings from those clinical trials as an oral presenter. https://cannmedevents.com/staci-gruber-phd/ Topics Discussed: Key findings from the MIND Program's longitudinal studies on medical cannabis use (improved cognitive performance and reductions in pain, anxiety, and sleep disturbances) Ongoing clinical trials the MIND Program is conducting on anxiety, bipolar disorder, and Alzheimer's The Women's Health Initiative at MIND (WHIM) investigating cannabis for gynecologic pain, menopause, and endometriosis Concerns about mislabeled cannabis products and unregulated hemp-derived products and more! Thanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medicinal cannabis brand founded to address the challenges of helping people and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer Hemp products are available nationwide and include a step-by-step usage guide and response tracker. Healer's distinctive product formulations and education are based on the latest research and work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Visit Healer.com or HealerCbd.com Additional Resources https://www.drstacigruber.com Social Media: @DrStaciGruber on X and Instagram Register for CannMed 25 Meet the CannMed 25 Speakers Review the Podcast CannMed Archive

Dr. Punya Nachappa is an Associate professor at Colorado State University in the Department of Agricultural Biology. Her research program focuses on understanding the interactions between plants and insect vectors to manage plant pests and diseases in hemp. At CannMed 25, Punya will present "Biology and Management of Hop Latent Viroid", which will describe the impact of HLVd on hemp yield and cannabinoids, explain how thrips and aphids transmit the viroid, and evaluate the efficacy of using chemical elicitors to control HLVd infections. During our conversation, we discussed: How Hop Latent Viroid has been reported in every hemp-growing state in the US and Canada How HLVd spreads through infected clones, mechanical contact, seeds, and insect vectors like aphids and thrips. Possible reasons why hemp varieties appear more resistant than cannabis varieties (i.e., genetic diversity and environmental factors) The tradeoffs associated with using chemical elicitors on infected plants: increased yield, but reduced cannabinoids. Strategies for preventing HLVD spread, including strict sanitation, insect monitoring, frequent testing, and breeding for genetic resistance. Thanks to This Episode's Sponsor: Advanced Nutrients. Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at AdvancedNutrients.com Additional Resources - Nachappa Lab Website (https://www.nachappalab.com/) - Register for CannMed 25 (https://cvent.me/emBPno) - Meet the CannMed 25 Speakers (https://cannmedevents.com/speakers/) - Review the Podcast (https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804) - CannMed Archive (https://cannmedevents.com/cannmed-video-archives/)

Dr. Michelle Peace is an internationally recognized forensic toxicologist and a Full Professor in the Department of Forensic Science at Virginia Commonwealth University. The National Institute of Justice has funded her team to study the proliferation of semi-synthetic THC analogs in the unregulated market and define their relevant biomarkers. Her work impacts public health and public safety policies and initiatives. At CannMed 25 Michelle will present “Why Some People “Green Out”? The Analysis of Unregulated “Hemp-derived” Cannabis Products”. Her team used a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to analyze unregulated hemp products. All the products they analyzed were mislabeled in some way, either misrepresenting the cannabinoids contained therein or their concentrations.  During our conversation we discuss What has caused the rise of semi-synthetic cannabinoids in the market?  How Michelle got involved testing unregulated hemp and cannabis products  Some of the adverse events that have occured from consuming semi-synthetic cannabinoids  How the LS-MS/MS method allows Michelle's team to see compounds other labs can't   How consumers can protect themselves from mislabeled products Whether federal legalization of cannabis would eliminate the semi-synthetic market  Thanks to This Episode's Sponsor: PRICH Biotech PRICH Biotech, Corp. is a vertically integrated company dedicated to the cultivation, manufacture and dispensing of medicinal Cannabis in Puerto Rico.  With over 500,000 square feet of state-of-the-art facilities, Prich uses the highest standards of agricultural and manufacturing practices to guarantee the highest standard of medicinal cannabis. Their mission is to offer a natural and unique experience through medicinal cannabis that raises the patient's well-being and quality of life. Learn more at prichbiotech.com.  Additional Resources Register for CannMed 25 Meet the CannMed 25 Speakers Review the Podcast CannMed Archive

Dr. Nicole Gauthier is a Professor and Extension specialist at the University of Kentucky.  Her program focuses on disease management of specialty crops including fruits, vegetables, and hemp.  In her Extension role, she develops educational and outreach programs to help growers manage disease through identification, understanding of pathosystems, and integration of management strategies. Her research program focuses on a range of hemp diseases, including Fusarium head blight, as well as stand establishment and seedborne transmission.  Dr. Gauthier's resources can be found at plantpathology.ca.uky.edu/extension/publications, on Facebook and Twitter at @KYPlantDisease, and on YouTube at @NicoleGauthier.  Nicole's team at the University of Kentucky recently published a fact sheet about Fusarium head blight in hemp plants, which caught my eye considering many of the cultivators we work with at Medicinal Genomics struggle with that pathogen. During our conversation, we discuss: The financial impact of fusarium on Hemp and cannabis crops The public health concerns due to Fusarium's production of harmful mycotoxins How growers often misidentify Fusarium head blight as Botrytis due to similar symptoms, leading to ineffective management strategies. Environmental conditions that increase the likelihood of a Fusarium infection Challenges for prevention and management, including a lack of effective fungicides and resistant cultivars Future Research to understand Fusarium spread, genetic resistance, and management techniques Thanks to this episode's Sponsor: Rare Earth Genomics. Rare Earth Genomics is a dynamic partnership formed with Texas A&M AgriLife, one of the world's leading research institutions, to accelerate hemp research and create tools for farmers. Their mission is to increase the likelihood of a successful harvest for farmers through genetic analysis and rigorous environmental testing of vigorous cultivars. Learn more at rareearchgenomics.com Additional Resources UK Plant Pathology resources and publications USDA hemp multistate group (S1084) resources page UK hemp website Register for CannMed 25 Meet the CannMed 25 Advisory Board Review the Podcast CannMed Archive

Ed Leclere and David McKillop have teamed up to create High Science, a new TV series premiering on YouTube TODAY November 27th featuring Medicinal Genomics and CannMed. David is an Emmy-award-winning producer with an impressive background in creating hit shows like Duck Dynasty and Pawn Stars. He brings his storytelling expertise to the cannabis space, teaming up with Ed Leclere to launch a show that's as entertaining as it is informative. High Science promises to take viewers on a journey through the world of cannabis, focusing on its therapeutic potential, the people who grow it, and the science that drives it forward. During our conversation, we discuss: Ed's personal health journey and how it inspired the show's creation The show's goal to make the medical science of cannabis more accessible to the public and reduce cannabis stigma. The challenges that cannabis entrepreneurs face in the form of strict regulations, financial challenges, and a thriving black market. How the series uses personal storytelling to balance education and entertainment. Why YouTube was chosen for its global reach and creative freedom compared to traditional networks. A glimpse into future seasons which may explore other plant medicines, such as mushrooms. Thanks to This Episode's Sponsor: High Science TV High Science TV shares the lively exploits of colorful characters around the world, trailblazing all things cannabis in pursuit of the modern-day gold rush. Father/son show hosts Rich Batenburg Jr. and Richard “Rick” Batenburg III explore legendary seed gurus, relentless cultivators, expansive growers, pioneering product makers and imaginative dispensary owners as they break the barriers of this new frontier. The storytelling unmasks the mystical powers of the ancient cannabis plant and its innumerable uses through dynamic entertainment. High Science premieres on YouTube November 27th at YouTube.com/@HighScienceTV. Additional Resources Watch High Science HighScience.com Register for CannMed 25 Meet the CannMed 25 Advisory Board Review the Podcast CannMed Archive

Kevelin Barbosa-Xavier is a PhD student in Plant Biotechnology at Universidade Estadual do Norte Fluminense Darcy Ribeiro (UENF) where she conducts research under the supervision of Thiago Motta Venancio. She is a computational biologist, investigating the genes and gene networks involved in plant secondary metabolic pathways and fiber production, specifically in the Cannabis sativa species. Kevelin and her team recently published a study titled Cannabis Expression Atlas: a comprehensive resource for integrative analysis of Cannabis sativa L. gene expression, along with a free online tool to help researchers analyze genomic sequence data. We discussed: The team's main objectives in creating the Cannabis Expression Atlas How our understanding of cannabis genomics compares to other commercial crops How gene expression data can advance plant breeding and genetic engineering Potential applications of the Cannabis Expression Atlas in commercial cannabis cultivation and more Thanks to This Episode's Sponsor: Medicinal Genomics Medicinal Genomics (MGC) uses its unmatched knowledge of the cannabis genome and the microbes affecting cannabis plants to create diverse testing solutions that improve crop yield, accelerate breeding programs, and ensure product safety. Growers and breeders use MGC's cannabis genome sequencing services to identify novel traits, stabilize genetics, and protect intellectual property. Additionally, Kannapedia.net provides bioinformatics and blockchain certification for cultivar authenticity. Learn more at medicinalgenomics.com Additional Resources Cannabis Expression Atlas: a comprehensive resource for integrative analysis of Cannabis sativa L. gene expression Cannabis Expression Atlas Register for CannMed 25 Meet the CannMed 25 Advisory Board Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

Laura Barrett, MBA, BSN, RN, known as “Nurse Laura,” is the Founder and Executive Director of the National Clinical Director Consortium and the Owner and Operator of Ask Nurse Laura. She serves on the boards of several non-profits, including the Connor Sheffield Foundation. Nurse Laura is dedicated to educating individuals and groups about cannabis and psychedelic medicine options, whether in small settings or large conference auditoriums.  Additionally, she is part of the teaching faculty at the University of Maryland's School of Pharmacy and New York University's Business School where she teaches multiple courses - including the collaborative development of a psychedelic elective course for the Masters of Cannabis Science and Therapeutics program. She also conducts training sessions with healthcare provider groups and nursing organizations, delving into state-specific regulations, products, and access for providers. Collaborating closely with pharmacists, providers, and fellow nurses in the cannabis industry, Nurse Laura promotes valuable educational resources for healthcare professionals, patients, and dispensary staff. Her mission is to enhance consistency and reliability in the educational opportunities available, specifically in healthcare. Nurse Laura has hands-on experience in various aspects of the cannabis industry, including cultivation, processing, dispensary operations, sales, marketing, and compliance. She emphasizes the importance of understanding laws and regulations, reviewing scientific research, and gathering patient data to create accessible presentations that support public health. Her balanced approach to cannabis and hemp integrates them into a holistic view of wellness.  Nurse Laura stays informed about current research on the medicinal use of cannabis and psychedelics to help patients and her peers assess the benefits and risks unique to everyone. She crafts tailored care plans incorporating well-established practices that she and her industry peers aim to standardize. Beloved by her patients for their improved health and respected by fellow practitioners for her perseverance and dedication, Nurse Laura is committed to advancing the evolving field of plant medicine therapeutics. Laura is currently working with the Connor Sheffield Foundation on an observational research study about the use of cannabis to treat symptoms of Post Traumatic Stress Disorder (PTSD).  During our conversation we discuss:  How cannabinoids affect trauma responses and support cognitive therapy  Details about the research study, including who should participate and how data will be collected  How patients use different routes of administration, cannabinoid ratios, and dosages to manage certain symptoms  The challenges of doing cannabinoid research and the need for standartization across the US  and more  Thanks to This Episode's Sponsor: McKinney RSA McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources Connor Sheffield Foundation PTSD Research Study Link AskNurseLuara.com National Clinical Director Consortium Cannabinoid modulation of brain activation during volitional regulation of negative affect in trauma-exposed adults Register for CannMed 25 Meet the CannMed 25 Advisory Board Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

With a BSc. in molecular biology and an MSc. in physiology, Liz has studied the human body through many lenses. The focus of her PhD program (Pharmacy) is to explore disorders that have directly impacted her life in the world of professional contact sports, and how cannabinoid products could potentially play a role in these.  As a member of the clinical trial team that was recently awarded funding from the NFL to study cannabinoids in concussion and pain, she is excited to bring new data to the literature exploring cannabinoids and athletics. Liz and her team recently published an extensive literature review titled Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real‑World Cannabinoid Applications In Sport, which establishes a foundation for their future research.   During our conversation, we discussed:  How Liz became interested in the therapeutic potential of cannabinoids Published literature that supports using cannabinoids for neuroinflammation and neurodegenerative disorders Her team's collaboration with the NFL and ongoing clinical trials focused on neuroinflammation and recovery in athletes, particularly after concussions Current use of cannabis in athletics and how sports organizations are changing their policies  Future directions of research  and more  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real‑World Cannabinoid Applications In Sport trainwithmaryjane.com Train with Mary Jane on Instagram Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

Megan Mbengue is the revolutionary force behind Trusted Canna Nurse. With over 10 years of nursing experience in diverse fields like oncology, labor delivery, and hospice care, she brings a unique perspective to her practice. She also holds national certifications in three nursing specialties and a Master of Science degree in Medical Cannabis Therapeutics. Codi Peterson is the Chief Science Officer at The Cannigma and a practicing pharmacist with a passion for cannabis-based medicine. Given his diverse pediatric pharmacy experience and knack for educating, he aims to educate as many as possible about the medicinal potential of cannabis Codi and Megan have launched a new IRB-approved survey through the University of California that aims to better understand the signs, symptoms, and challenges of CHS. They want to understand the key indicators of this condition, hear about any remedies that work, and learn more about navigating healthcare as a CHS patient.  If you or someone you know has suffered from CHS (and are over 18), please take a moment to fill out their survey. Not only will you be helping this vital research, but participants will be entered into a drawing to win one of three $100 gift cards. I've put a link in the show description so it's easy to find.  During our conversation, we discuss:  Overview of CHS symptoms   Early Symptoms and the Prodrome Phase  Clinical experiences treating CHS patients  The Potential Causes   Challenges in diagnosing CHS  Treatment and Abstinence from Cannabis  Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more.  Learn more at trustedcannanurse.com  Additional Resources Take the CHS Survey! Cannabinoid Hyperemesis Syndrome What You Need to Know [Video] what-is-chs.com Connect with Megan (Instagram, LinkedIn) Connect with Codi (Instagram, LinkedIn) Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

Justin Esquivel is CEO & Geneticist, Green Luster Phenos™ and has been an influencer and leader in the cannabis industry for 15 years. Esquivel was the head grower and geneticist of an indoor commercial-scale cultivation operation back in 2012.  Justin has consulted with over 100 cannabis facilities, 72 of which operate commercial canopies.  Esquivel provides home growers with pest and bacteria-resistant genetics in seed and breeders' cut form on a global scale!  He brings standard operating procedures to a gold standard.  His one-of-a-kind approach to plasticity breeding has sparked tons of interest across the globe.  Esquivel also specializes in Cannabis Tissue Culture & Selective Homozygous Breeding, enabling his company to bring exotic tailored offspring to growers globally!During our conversation, we discuss:  Justin's background in traditional ag and how that applies to cannabis  How he uses tissue culture to store genetics and eliminate pathogens  The process for creating stable cannabis varieties How purposely introducing pests into the breeding room helps select for resistance traits  The application of analytical tools, such as PCR, HPLC, and marker-assisted breeding  Thanks to this episode's Sponsor: Rare Earth Genomics.  Rare Earth Genomics is a dynamic partnership formed with Texas A&M AgriLife, one of the world's leading research institutions, to accelerate hemp research and create tools for farmers. Their mission is to increase the likelihood of a successful harvest for farmers through genetic analysis and rigorous environmental testing of vigorous cultivars.  Learn more at rareearthgenomics.com  Additional Resources:  greenlusterphenos.com Review the Podcast CannMed Archive

Dr. John Streicher is a Professor in the Department of Pharmacology in the College of Medicine at the University of Arizona. He has built a long-term research program focused on finding improved treatments for pain. This has encompassed multiple approaches over the years, including testing cannabinoid and non-cannabinoid constituents of Cannabis sativa, identifying new ways to target opioid receptor signaling, and identifying new receptor targets in the body for pain relief. His lab works on both the basic science knowledge of how these systems work and also works to create new drugs for human therapy. During our conversation, we discussed: The basics of terpenes. What they are and their role in cannabis The cannabimimetic effects of terpenes and their synergistic effects with cannabinoids What levels of terpenes are needed to get a therapeutic effect A recent study showing terpenes can relieve chronic neuropathic pain Combining terpenes with other drugs, such as opioids, to get better pain relief at lower doses Which terpenes provide the best pain relief Thanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medicinal cannabis brand founded to address the challenges of helping people and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer Hemp products are available nationwide and include a step-by-step usage guide and response tracker. Healer's distinctive product formulations and education are based on the latest research and work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Visit Healer.com or HealerCbd.com Additional Resources: Terpenes are Cannabimimetic and Enhance Cannabinoid Activity Terpenes Relieve Chronic Pain A Review Article of Terpenes in Pain A Screen of Minor Cannabinoids in Pain The University of Arizona Comprehensive Center for Pain and Addiction Review the Podcast CannMed Archive

Dr. Harold Han is Chief Science Officer and co-founder of Vertosa, and the pioneer in water compatible cannabinoid ingredients for infused products. Harold designed the industrial leading cannabis emulsions that are widely applied in the cannabis beverage brands. Harold holds 16 patents in emulsion applications, and prior to founding Vertosa, he led a team that developed the emulsification oil for Bio Rad's Digital Droplet PCR system. Harold also publishes a regular series explaining the science of cannabis for product makers under the monicker "The Happy Chemist" — a nickname you'll understand after you watch the interview. One of his recent articles describes the different factors that contribute to cannabis beverage potency loss, which is a challenge for beverage brands. In fact, in regulated markets it's common to see a 10-15% variation in potency compared to the label claim. In unregulated hemp-derived beverages, it can be even higher. During the conversation we discuss The difference between cannabis beverages and alcoholic beverages What happens when cannabinoids oxidize How to put THC into water-based products using physical and chemical processes How every aspect of the supply chain can lead to potency loss in cannabis beverages Which beverage ingredients hasten potency loss How packaging conditions can affect scalping and oxidation rates Thanks to This Episode's Sponsor: Vertosa Vertosa creates industry-leading active ingredients for infused product makers. Their patent-pending nano- and micro-emulsions are carefully designed for the specific needs of each customer, and their pre-suspended aqueous solutions empower them to create incredibly homogenous and stable products while maximizing bioavailability, clarity, and taste. Learn more at Vertosa.com Additional Resources Happy Chemist Article Series The Cannabis Beverage Manufacturing Handbook Review the Podcast CannMed Archive

Dr. Deb Kimless has been in the medical cannabis field since 2013 where her diverse involvement spans many areas including cannabis cultivation, processing, formulation, testing, patient care, and conducting research. She consults within the industry as an advisor for companies who are interested in novel formulations specific to medical conditions, develops protocols, obtains IRB approval, conducts clinical trials, and helps to publish the results. At CannMed 24, Deb presented a poster that shared data from an open-label clinical trial investigating using a cannabinoid-enhanced topical cream for alleviating Restless Leg Syndrome. RLS is condition that affects up to 10% of the US population, including Deb. She found relief using a CBDA-based topical cream and is working with the product manufacturer to conduct clinical trials that demonstrate its effectiveness.  During our conversation, we discuss:  The symptoms of RLS and possible causes  Deb's own struggles with RLS  Why many conventional and pharmaceutical treatments of RLS fall short  Why CBDA appears to be effective at alleviating RLS symptoms  Why a transdermal approach is better than ingesting or inhaling cannabinoids  Results from the open label clinical trial including some remarkable success stories  Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more.  Learn more at trustedcannanurse.com  Additional Resources chylorelief.com - USE CODE "CANNMED20" for 20% OFF! Email Deb - dkimless@gmail.com Review the Podcast CannMed Archive

David Aronson is a cannabis educator who since 2018 has directly educated more than 5,000 health professionals nationwide on the medical applications of cannabis. He is on the faculty for PESI, one of the nation's largest providers of professional continuing education, and he independently provides seminars for health professionals nationwide. I learned during our conversation that David also has post-treatment Lyme disease, which is a condition that causes fatigue, neuropathic pain, brain fog, forgetfulness, and other chronic symptoms that he treats with cannabis. His experience made him curious whether others have found success using cannabis to treat persistent Lyme. He shared his findings at CannMed 24 as a poster presentation and with me in the conversation you are about to hear.  We covered:  What is Lyme disease and how does one acquire it The different stages of Lyme disease  Treatments that are available to treat chronic Lyme disease  How David collected data for his study  Which types of products are effective for chronic Lyme symptoms  and more  Thank You to This Episode's Sponsor: McKinney RSA  McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources lymedisease.org ilads.org strainprint.ca Review the Podcast! CannMed Archive

Zac has been involved in the cannabis industry since 2005. He has had experience with all kinds of growing environments. From outdoor plots in Northern California to warehouses throughout the United States, his journey has taken him to almost every corner of the country. Zac worked at some of the most reputable supply companies and cultivations before landing his job at BioSafe Systems. He is the National Cannabis Specialist for the company, a position that did not exist before Zac was hired. He has comprehensive knowledge of all aspects of cultivation but specializes in integrated pest management (IPM). He has even written the book “Clean Growing: Integrated Pest Management for Cannabis Growers: The Ultimate Guide to Clean Crops & Safe Cultivation Practices That Protect Growers & Consumers” that is available to growers on Amazon. During our conversation we discuss: How Zac got involved with IPM What is IPM and why it's important to cannabis growers How cannabis growers can implement IPM into their operations  Common pests and pathogens that cannabis growers are battling  Common mistakes cannabis growers make when it comes to IPM  and more  Thanks to This Episode's Sponsor: Advanced Nutrients Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community, and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at advancednutrients.com  Additional Resources Clean Growing: Integrated Pest Management for Cannabis Growers: The Ultimate Guide to Clean Crops & Safe Cultivation Practices That Protect Growers & Consumers Review the Podcast! CannMed Archive

We will be back with new episodes of the CannMed Coffee Talk Podcast next month! Please be patient as we recharge following the CannMed 24 Innovation and Investment Summit, and prepare for next year's event! Be sure to sign up for email alerts at CannMedEvents.com so you will receive notifications when we publish the CannMed 24 oral presentation videos and announce details for CannMed 25!

Dr. Shannon Smith received his PhD in molecular biosciences from Middle Tennessee State University. There his research focused on plant biotechnology, with work in Cannabis, Panax, and Vitis tissue culture and manipulation. This led to the development of new and unique technologies for the production of both plants and secondary metabolites. He later founded Greenway Lab, a plant biotech company that collaborates with agricultural partners to implement plant biotech solutions to botanical challenges facing the modern agricultural industry. During our conversation, we discuss: How recent advances in plant tissue culture can address major problems faced by the Cannabis industry How rapid, reliable propagation of identical daughter plants can be achieved in tissue culture How long-term storage of explant tissues can be used to regenerate whole plants How developments in meristematic tissue culture protocols can eliminate viral contamination of plant tissues And more! Additional Resources Greenwaylab.co dr.smith@gwlabtn.com Medical Cannabis and Industrial Hemp Tissue Culture: Present Status and Future Potential Cryopreservation of 13 Commercial Cannabis sativa Genotypes Using In Vitro Nodal Explants Initiation, growth and cryopreservation of plant cell suspension cultures ELIMINATION OF HOP LATENT VIROID FROM HOP PLANTS BY COLD TREATMENT AND MERISTEM TIP CULTURE Under siege: virus control in plant meristems and progeny

Tim Lefever is the Director of Discovery at Nalu Bio. He is an experienced Director with a demonstrated history of 20+ years of preclinical in vivo research and leading effective teams at organizations such as Canopy Growth and Research Triangle Institute. He has authored or co-authored numerous manuscripts and presented research findings at a variety of scientific conferences over the past 20 years. At CannMed 24, Tim will present "Characterization of Less Studied Cannabis Phytochemicals” which investigates the pharmacological, physicochemical, and basic toxicological characteristics of cannabis phytochemicals. During our conversation, we discuss: How Tim and his team choose which phytochemicals to study What makes the varin cannabinoids particularly interesting The difference between chemically derived compounds vs plant-derived compounds Which phytochemicals show the most promise Modifying phytochemicals to improve their effectiveness Thanks to This Episode's Sponsor: Brains Bioceutical Brains Bioceutical is a global leader in EU-GMP-certified production of naturally-sourced active pharmaceutical ingredients for the pharmaceutical and nutraceutical industries. With a unique suite of licences, Brains Bioceutical is one of the only natural plant-based phytochemical API manufacturers in commercial production today, and is involved in academic and clinical trials across the globe. Learn more at brainsbioceutical.com Additional Resources nalubio.com Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Dr. Kimberly Gwinn is a Professor of Entomology and Plant Pathology at the University of Tennessee. Her lab currently investigates natural products that are produced by plants and microbes and their uses as medicines and as bio-pesticides.  At CannMed 24 she will present Hemp Processing by-products as Biopesticides which describes her team's work using terpene-rich industrial hemp by-products to control plant diseases and pests.  We discuss:  Why terpenes are effective biopesticides  Which pathogens and pests terepene-rich biopesticide can fight  What are nanaemulsions and why they are important in this application  How this technology can open up a new revenue stream for growers  The regulatory lift for getting biopesticides approved  and more  Thanks to this episode's Sponsor: Rare Earth Genomics.  Rare Earth Genomics is a dynamic partnership formed with Texas A&M AgriLife, one of the world's leading research institutions, to accelerate hemp research and create tools for farmers. Their mission is to increase the likelihood of a successful harvest for farmers through genetic analysis and rigorous environmental testing of vigorous cultivars.  learn more at rareearchgenomics.com  Additional Resources Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Megan Mbengue is the revolutionary force behind Trusted Canna Nurse. Recognizing a gap between elderly patients and cannabis, Megan sought to provide that demographic with the extra hand-holding and guidance they need to have the best possible experience. With over a decade of nursing experience in diverse fields like oncology, labor delivery, and hospice care, she brings a unique perspective to her practice. At CannMed 24 Megan will be participating in a Cannabis Nursing Panel and presenting a poster titled “Microdosing Psilocybin for Cannabis Dependency: A Nurse Led Intervention”  During our conversation, we discuss:  The important role nurses play in cannabis medicine How brands can tap into the expertise cannabis nurses have How psilocybin can be used to treat addictive behavior  The results from Trusted Canna Nurses 6-week beta for using psilocybin to treat cannabis dependency  and more  Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more.  Learn more at trustedcannanurse.com  Additional Resources Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

TJ Martin is the VP of R&D at Abstrax, a company that specializes in the research, development, and production of botanically derived and cannabis-inspired terpenes.  TJ and his team recently published a paper that identified several non-terpenoid compounds that are responsible for the unique aromas associated with exotic cannabis varieties, including the berry, tropical, candy, and fruity notes found in Zkittlez and Gelato as well as the rich, intense, chemical scents found in GMO. This research opens up a new world of aromatic compounds and challenges the idea of classifying cultivars based on terpenes alone.  We discuss: How cannabis aroma affects consumer and patient experience  The variety of aromas the cannabis plant can produce and how it compares to other plants  Define exotic cannabis varieties and compare them to more prototypical cultivars  Why terpenes alone do not tell the entire aroma story in exotic cannabis varieties  How to communicate information about non-terpeninoid compounds to consumers and patients in a meaningful way  Thanks to This Episode's Sponsor: Agilent Technologies Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly. Learn more at agilent.com Additional Resources Minor, Nonterpenoid Volatile Compounds Drive the Aroma Differences of Exotic Cannabis Abstraxtech.com  [Podcast] Discovering New Aromatic Compounds in Cannabis with TJ Martin Cannasulfur Compounds: A New Class of Secondary Metabolites Discovered in Cannabis Cannabis Aroma Predicts User Experience with Adie Rae, PhD The Nose Knows: Aroma, but Not THC Mediates the Subjective Effects of Smoked and Vaporized Cannabis Flower Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field. Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 24 this year as one of the medical practicum instructors and an oral presenter, presenting “The Art and Science of Combining Cannabinoids for Treatment Success” * We discuss: What attendees can expect from CannMed Medical Practicum The expansion of avialble cannabinoids and how Dustin evaluates new options Which Cannabinoid Dustin would choose if he could only use one to treat patients The difference between acidic and neutral forms of cannabinoids The process for combining cannabinoids Challenging old assumptions about the benefits of combining CBD and THC Thanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer's distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Learn More at healer.com Additional Resources Healer.com Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive